AR040010A1 - Derivados de (imidazol-1-il-metil)-piridazina - Google Patents
Derivados de (imidazol-1-il-metil)-piridazinaInfo
- Publication number
- AR040010A1 AR040010A1 ARP030101685A ARP030101685A AR040010A1 AR 040010 A1 AR040010 A1 AR 040010A1 AR P030101685 A ARP030101685 A AR P030101685A AR P030101685 A ARP030101685 A AR P030101685A AR 040010 A1 AR040010 A1 AR 040010A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- neurodegeneration
- compounds
- chronic
- forms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005750 substituted cyclic group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) ó (2) donde A es un grupo cíclico insustituido o sustituido; y R es hidrógeno o alquilo inferior; y sales de adición ácida farmacéuticamente aceptables de los mismos. Se ha demostrado que los compuestos de las fórmulas (1) y (2) son buenos bloqueantes específicos del subtipo de receptor NMDA NR-2B. Las posibles indicaciones terapéuticas para estos compuestos incluyen formas aguadas de neurodegeneración causadas, p.ej. por apoplejía y traumas cerebrales, y formas crónicas de neurodegeneración tales como la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, LAS (esclerosis lateral amiotrópica) y neurodegeneración asociada con infecciones bacterianas o virales y, además, depresión y dolor crónico y agudo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02010217 | 2002-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040010A1 true AR040010A1 (es) | 2005-03-09 |
Family
ID=29433072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101685A AR040010A1 (es) | 2002-05-16 | 2003-05-15 | Derivados de (imidazol-1-il-metil)-piridazina |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7005432B2 (es) |
| EP (1) | EP1506190B1 (es) |
| JP (1) | JP4267569B2 (es) |
| KR (1) | KR100632868B1 (es) |
| CN (1) | CN1312151C (es) |
| AR (1) | AR040010A1 (es) |
| AT (1) | ATE329912T1 (es) |
| AU (1) | AU2003242542B2 (es) |
| BR (1) | BR0311177A (es) |
| CA (1) | CA2485926C (es) |
| CL (1) | CL2004001251A1 (es) |
| CY (1) | CY1105159T1 (es) |
| DE (1) | DE60306152T2 (es) |
| DK (1) | DK1506190T3 (es) |
| ES (1) | ES2265581T3 (es) |
| HR (1) | HRP20041060B1 (es) |
| IL (1) | IL164922A (es) |
| MA (1) | MA27117A1 (es) |
| ME (1) | MEP76708A (es) |
| MX (1) | MXPA04011253A (es) |
| NO (1) | NO329605B1 (es) |
| NZ (1) | NZ536310A (es) |
| PL (1) | PL211340B1 (es) |
| PT (1) | PT1506190E (es) |
| RS (1) | RS51200B (es) |
| RU (1) | RU2317294C2 (es) |
| SI (1) | SI1506190T1 (es) |
| TN (1) | TNSN04224A1 (es) |
| WO (1) | WO2003097637A1 (es) |
| ZA (1) | ZA200408789B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
| WO2006117052A1 (de) | 2005-05-03 | 2006-11-09 | Merck Patent Gmbh | Organische elektrolumineszenzvorrichtung und in deren herstellung verwendete boronsäure- und borinsäure-derivate |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| JP5315710B2 (ja) * | 2008-02-07 | 2013-10-16 | セントラル硝子株式会社 | １−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法 |
| DE102008015033A1 (de) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
| NZ588698A (en) * | 2008-03-27 | 2012-06-29 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| EP2393360B1 (en) | 2009-02-05 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
| EP2602255B1 (en) * | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| WO2012019106A2 (en) * | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| PT3180329T (pt) * | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
| DE102015011861B4 (de) | 2015-09-10 | 2018-03-01 | Rudolf Schindler | Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren |
| PL3386591T3 (pl) | 2015-12-09 | 2021-02-22 | Novartis Ag | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
| CA3014314A1 (en) | 2016-02-10 | 2017-08-17 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| US10874104B2 (en) | 2016-02-18 | 2020-12-29 | Syngenta Participations Ag | Pesticidally active pryazole derivatives |
| WO2017158147A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| WO2017158151A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| EP3558318B1 (en) | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
| US11447503B2 (en) | 2019-06-14 | 2022-09-20 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as GLUN2B receptor modulators |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| RS64359B1 (sr) | 2018-08-03 | 2023-08-31 | Novartis Ag | Heteroaromatični modulatori nmda receptora i njihove upotrebe |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| PH12021552839A1 (en) | 2019-06-14 | 2022-10-03 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| CN113993583A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途 |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| EP3983075A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| CN114478210A (zh) * | 2022-02-26 | 2022-05-13 | 江苏壹药新材料有限公司 | 一种7-氯萘-2-甲醛的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| ES2174220T3 (es) | 1996-03-08 | 2002-11-01 | Hoffmann La Roche | Uso de derivados de 4-fenil-3,6-dihidro-2h-piridilo como agentes bloqueantes de subtipos de receptores nmda. |
| CA2220649C (en) * | 1996-12-03 | 2007-02-13 | F. Hoffmann-La Roche Ag | 4-hydroxy-piperidine derivatives |
| US6015824A (en) * | 1998-02-10 | 2000-01-18 | Hoffmann-La Roche Ag | Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders |
| TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
| ATE257827T1 (de) * | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| CN1178911C (zh) | 2000-04-20 | 2004-12-08 | 弗·哈夫曼-拉罗切有限公司 | 吡咯烷与哌啶衍生物和它们用于治疗神经变性疾病的用途 |
| US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
| US7022882B2 (en) | 2000-10-06 | 2006-04-04 | The Regents Of The University Of California | NMDA receptor channel blocker with neuroprotective activity |
| CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
| DE10120159A1 (de) | 2001-04-25 | 2002-10-31 | Merck Patent Gmbh | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
-
2003
- 2003-05-09 US US10/434,955 patent/US7005432B2/en not_active Expired - Fee Related
- 2003-05-15 AR ARP030101685A patent/AR040010A1/es active IP Right Grant
- 2003-05-16 ME MEP-767/08A patent/MEP76708A/xx unknown
- 2003-05-16 EP EP03752750A patent/EP1506190B1/en not_active Expired - Lifetime
- 2003-05-16 CN CNB038111926A patent/CN1312151C/zh not_active Expired - Fee Related
- 2003-05-16 DK DK03752750T patent/DK1506190T3/da active
- 2003-05-16 NZ NZ536310A patent/NZ536310A/en not_active IP Right Cessation
- 2003-05-16 DE DE60306152T patent/DE60306152T2/de not_active Expired - Lifetime
- 2003-05-16 RU RU2004136979/04A patent/RU2317294C2/ru not_active IP Right Cessation
- 2003-05-16 PT PT03752750T patent/PT1506190E/pt unknown
- 2003-05-16 AU AU2003242542A patent/AU2003242542B2/en not_active Ceased
- 2003-05-16 WO PCT/EP2003/005151 patent/WO2003097637A1/en not_active Ceased
- 2003-05-16 RS YUP-985/04A patent/RS51200B/sr unknown
- 2003-05-16 SI SI200330332T patent/SI1506190T1/sl unknown
- 2003-05-16 BR BR0311177-6A patent/BR0311177A/pt not_active IP Right Cessation
- 2003-05-16 AT AT03752750T patent/ATE329912T1/de active
- 2003-05-16 ES ES03752750T patent/ES2265581T3/es not_active Expired - Lifetime
- 2003-05-16 JP JP2004505370A patent/JP4267569B2/ja not_active Expired - Fee Related
- 2003-05-16 CA CA002485926A patent/CA2485926C/en not_active Expired - Fee Related
- 2003-05-16 PL PL374224A patent/PL211340B1/pl unknown
- 2003-05-16 MX MXPA04011253A patent/MXPA04011253A/es active IP Right Grant
- 2003-05-16 HR HR20041060 patent/HRP20041060B1/xx not_active IP Right Cessation
- 2003-05-16 KR KR1020047018485A patent/KR100632868B1/ko not_active Expired - Fee Related
-
2004
- 2004-05-24 CL CL200401251A patent/CL2004001251A1/es unknown
- 2004-10-28 IL IL164922A patent/IL164922A/en not_active IP Right Cessation
- 2004-10-28 NO NO20044666A patent/NO329605B1/no not_active IP Right Cessation
- 2004-10-29 ZA ZA2004/08789A patent/ZA200408789B/en unknown
- 2004-11-11 TN TNP2004000224A patent/TNSN04224A1/fr unknown
- 2004-11-12 MA MA27943A patent/MA27117A1/fr unknown
-
2006
- 2006-08-22 CY CY20061101161T patent/CY1105159T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040010A1 (es) | Derivados de (imidazol-1-il-metil)-piridazina | |
| DOP2011000135A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
| UY26782A1 (es) | Derivados del benzotiazol | |
| UY30426A1 (es) | Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones. | |
| CU23105A3 (es) | DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS | |
| UY30408A1 (es) | Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| UY26681A1 (es) | 4-bencil-1-{2-(4-hidroxi-fenoxi)-etil)-piperidina-3,4-diol | |
| MX9307810A (es) | Heterociclicos no aromaticos sustituidos con aminometileno. | |
| CR8531A (es) | Compuestos y procedimientos para su uso | |
| UY30617A1 (es) | Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones | |
| ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
| AR082498A1 (es) | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide | |
| EA200401053A1 (ru) | Оксо-азабициклические соединения | |
| AR075626A1 (es) | Metodos para administrar (4ar,10ar)-1-n- propil-1,2,3,4,4a,5,10,10a- octahidro -benzo (g) quinolin-6,7-diol y sus composiciones farmaceuticas. uso. | |
| EA200800303A1 (ru) | Применение производных и аналогов тиазола при нарушениях, вызванных свободными жирными кислотами | |
| AR037249A1 (es) | Compuestos derivados de piridina, un procedimiento para prepararlos y medicamentos que los contienen | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| PA8581201A1 (es) | Nuevos derivados de tiazol | |
| BR0208812A (pt) | Derivados fenil heterociclil éter como inibidores de recaptação de serotonina | |
| PA8496601A1 (es) | Derivados de piperidin - etansulfonil | |
| AR050956A1 (es) | Derivados de bencimidazol; sintesis de los mismos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por ligandos del receptor cb1. | |
| AR063924A1 (es) | Analogos de pirazol | |
| ECSP045426A (es) | (imidazol-1-il-metil)-piridazina como bloqueador del receptor nmda |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |